Genprex announced that new research identifying TROP2 expression as a potential predictive biomarker of response to its lead drug candidate, Reqorsa (quaratusugene ozeplasmid), will be presented at the 2026 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona. The research indicates that low TROP2 expression is associated with resistance to REQORSA across multiple preclinical models of non-small cell lung cancer (NSCLC) and is supported by analysis of pretreatment tumor biopsies from patients enrolled in a clinical trial evaluating the gene therapy product. If confirmed, this finding could help enhance clinical trials by recruiting more applicable patients and potentially deliver more effective treatment options. Genprex operates as a clinical-stage biotechnology company developing gene therapies for cancer and diabetes.
